# Gut Resistome of NSCLC Patients Treated with Immunotherapy:A Summary
### Haseeb Manzoor1, Yetunde Mary Alo1, Nada EIHadidy1, Sarani1
#### 1 AMR in Cancer

### Graphical Summary
![image](https://github.com/user-attachments/assets/5effeb91-ab26-43b3-a10f-15960e646405)
## Visual Summary
https://www.linkedin.com/posts/haseebmanzoor_hackbio2024-amrincancer-nsclc-activity-7238226331333799936--TRW?utm_source=share&utm_medium=member_desktop

## Crux of the Study
This study explores the role of the gut Resistome i.e., the collection of antibiotic resistance genes (ARGs) in determining immunotherapy outcomes in non-small cell lung cancer (NSCLC) patients [1]. Immunotherapy, particularly immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 pathways, has revolutionized cancer treatment by enabling the immune system to combat tumors more effectively. However, patient responses to ICIs vary widely, and the study investigates how the gut resistome, influenced by antibiotic use and smoking, affects these responses.
The research involved 30 advanced NSCLC patients undergoing immunotherapy with drugs such as nivolumab, pembrolizumab, and atezolizumab. Using targeted metagenomics, stool samples were analyzed to assess the composition and abundance of ARGs. Findings revealed that patients with progressive disease (PD) had a more diverse and abundant resistome compared to those with stable disease or partial response. Antibiotic use, particularly before or during immunotherapy, was associated with a significant expansion of ARGs, notably those conferring resistance to vancomycin, macrolides, and tetracyclines. Smoking further increased the presence of ARGs, particularly those linked to vancomycin resistance.
Key ARGs identified in patients with poor outcomes included lincosamides (lnuC), cephalosporins (blaEC), and fosfomycin (fosA). These genes were found to negatively correlate with progression-free survival (PFS) and overall survival (OS), suggesting that the resistome may serve as a predictive marker for immunotherapy efficacy. The study also highlighted that traditional reliance on PD-L1 expression as the sole biomarker for ICI response is insufficient, and the resistome offers a complementary factor that influences patient prognosis.
Despite its valuable findings, the study's small sample size (30 patients) and lack of a control group limit the generalizability of the results. Further research with larger cohorts is needed to validate the resistome's role in shaping immunotherapy outcomes and to explore the potential for modifying the gut microbiome to improve patient responses.

## Reference
[1]	E. Iwan et al., “Gut resistome of NSCLC patients treated with immunotherapy,” Front Genet, vol. 15, 2024, doi: 10.3389/FGENE.2024.1378900.

